MVA-S(3P) (Vaccine Candidate)
In August 2023, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool signed a worldwide licence with the Spanish National Research Council (CSIC) for a vaccine candidate based on the MVA vector platform, a highly attenuated Modified Vaccinia virus Ankara (MVA) vector that has been engineered to express a prefusion-stabilized human codon-optimized full-length SARS-CoV-2 spike (S) protein.
MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for this technology by submitting an e-mail to C-TAPvaccines@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
|Aim of the Licence
|To facilitate the manufacture and commercialisation of COVID-19 vaccine around the world.
|Any product that is covered by the Patents or uses the know-how or material.
|CSIC to provide all necessary know-how and materials (including the premaster virus seed for MVA-CoV2-S(3P) and unmodified derivatives) to the licensees.
The licence does not include any Know-How held by Biofabri.
|Field of use
|Scope of the grant
|Non-exclusive right to grant sublicences to develop the licensed patents/know-how/material into licensed products, and to commercialise licensed products.